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Purpose: Long duration of type 2 diabetes mellitus
(T2DM) is associated with progressive β-cell loss and
may pose a challenge to maintenance of good glycemic
control. This study aimed to assess the efﬁcacy and
safety of the dipeptidyl peptidase-4 inhibitor linaglip-
tin in an understudied population of patients with
long-standing T2DM.
Methods: Data from 202 individuals with T2DM
for 410 years were pooled from 2 randomized,
placebo-controlled, Phase III trials. Participants re-
ceived either linagliptin 5 mg once daily (n ¼ 122) or
placebo (n ¼ 80) for 24 weeks as an add-on to their
current glucose-lowering therapy.
Findings: Long-standing T2DM was associated
with older age (mean [SD], 69.1 [10.0] years) and a
high prevalence of diabetes-related complications
(78% with diabetic kidney disease and 83% with
macrovascular disease). The mean baseline glycosy-
lated hemoglobin (HbA1c) level was 8.22% (1.08%),
and mean baseline fasting plasma glucose level was
161.8 (49.2) mg/dL. Linagliptin signiﬁcantly improved
glycemic control after 24 weeks, with a placebo-
adjusted mean change in HbA1c from baseline of
0.66% (95% CI, 0.95 to 0.38; P o 0.0001).
This change was accompanied by a signiﬁcant reduc-
tion in fasting plasma glucose, with a placebo-adjusted
mean change from baseline of 15.5 mg/dL (95% CI,
29.6 to 1.3; P ¼ 0.0323) at week 24. Overall,
linagliptin was well tolerated, with drug-related ad-
verse events in 21.3% and 16.3% of the linagliptin
and placebo groups, respectively. Investigator-
reported hypoglycemia occurred more often with
linagliptin (25.4%) compared with placebo (12.5%).November 2014However, no severe hypoglycemic events were re-
ported with linagliptin. Moreover, in patients not
receiving concomitant sulfonylureas, the incidence of
hypoglycemia with linagliptin (12.5%) was similar to
that with placebo (12.2%). Patients’ mean weight
remained unchanged in both groups.
Implications: This pooled analysis found that lina-
gliptin was well tolerated and signiﬁcantly improved
hyperglycemia in a clinically challenging population of
patients with long-standing T2DM (410 years).
Although T2DM is commonly associated with dimin-
ished β-cell function, the extent of glucose lowering was
similar to that in linagliptin trials, which largely included
patients in earlier stages of the disease. Thus, this obser-
vation supports the hypothesis that regulation of gluca-
gon release from pancreatic α cells may be of particular
relevance for improving hyperglycemia in patients with
long-term T2DM (NCT01194830 and NCT01084005).
(Clin Ther. 2014;36:1595–1605) & 2014 The Authors.
Published by Elsevier HS Journals, Inc.
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type 2 diabetes mellitus.INTRODUCTION
The rapidly growing prevalence of type 2 diabetes
mellitus (T2DM),1 together with an overall increase1595
Clinical Therapeuticsin life expectancy, has led to rising numbers of
patients with a long history of this condition. Recent
evidence also indicates that 425% of adults aged
Z65 years in the United States have been diagnosed
with diabetes.2 Furthermore, in contrast to demo-
graphic changes of the overall population, the age of
onset of T2DM has dropped,3 and the condition
has now become more common in younger adults,
with growing numbers even in adolescents and
children.4–7 Over time, these shifting dynamics will
lead to increased numbers of middle-aged patients
presenting with a long history of T2DM.
The clinical management of patents with long-term
T2DM is challenging because of an increased preva-
lence of microvascular and macrovascular complica-
tions, as well as related comorbidities. Polypharmacy
regimens are therefore frequently used in such patients
to control hyperglycemia, diabetes-related complica-
tions, and multiple comorbidities. To add further
complexity, long-term T2DM is accompanied by
substantially impaired β-cell function.8–10 The pro-
gressive loss of β-cell mass and function is known to
impair the glucose-lowering potential of insulin secre-
tagogues (particularly sulfonylureas), and it may also
explain why most patients will eventually experience
monotherapy or even failure of combination therapy
with oral antidiabetes (OAD) treatments.10–15
The dipeptidyl peptidase-4 (DPP-4) inhibitors rep-
resent a class of glucose-lowering agents that enhance
the actions of glucagon-like peptide 1 (GLP-1) by
preventing its enzymatic degradation.16 GLP-1 stim-
ulates insulin secretion from pancreatic β cells in a
glucose-dependent manner. Furthermore, it suppresses
glucagon secretion from α cells, enhances satiety, and
reduces food intake. Preclinical studies have also
demonstrated proliferative and antiapoptotic actions
of GLP-1, which lead to expansion of β-cell mass. The
insulinotropic action of DPP-4 inhibitors exerted by
GLP-1 is thought to be the main contributing factor to
their glucose-lowering effects; however, DPP-4 inhib-
itors have also been shown to decrease postprandial
glucagon secretion,17–20 and results from a 2-year
study speciﬁcally addressing the effect of DPP-4
inhibition on postprandial glucagon secretion re-
ported suppression of glucagon secretion.17
DPP-4 inhibitors are generally well tolerated,
and, in contrast to other insulin secretagogues, their
glucose-dependent mechanism of action is associated
with a very low risk for hypoglycemia.21 Approved1596DPP-4 inhibitors can be used in a broad range of
T2DM patients, including those at advanced stages of
renal insufﬁciency. Dosage adjustment is required for
all members of the drug class except linagliptin.
Linagliptin could therefore be particularly useful to
clinicians treating individuals with long-standing
T2DM, a population that may present at older age
and/or with increased prevalence of microvascular
complications, both of which are known to be
associated with impaired renal function. However,
clinical evidence for DPP-4 inhibitors in this speciﬁc
population is scarce. We therefore conducted a retro-
spective analysis to investigate the safety and efﬁcacy
of linagliptin in patients with a long history of this
condition, deﬁned as a reported T2DM duration of
410 years.
PATIENTS AND METHODS
Patient Population
This retrospective analysis pooled data from
two 24-week, randomized, double-blind, placebo-
controlled, Phase III trials of linagliptin. In the pivotal
linagliptin clinical development program, time since
diagnosis of T2DM was captured semiquantitatively
by using the following predeﬁned categories: up to
1 year, 41 to 5 years, and 45 years. Two Phase IIIb
trials also included the category 410 years, and the
pooled analysis presented here includes only patients
from those trials with a reported T2DM duration of
410 years. Trial NCT01194830 comprised adult
T2DM patients who self-reported their race as black
or African American, were receiving r1 OAD treat-
ment, and had a glycosylated hemoglobin (HbA1c)
level of 7.5% to 11.0% at screening (N ¼ 226).22
Trial NCT01084005 comprised patients aged Z70
years, with an HbA1c level Z7.0% at screening who
had been treated and were stable for at least 8 weeks
with metformin and/or a sulfonylurea and/or basal
insulin (N ¼ 241).23
Individual study protocols were approved by rele-
vant local independent ethical committees or institu-
tional review boards. All trials were conducted
according to the Declaration of Helsinki and the
International Conference on Harmonised Tripartite
Guideline for Good Clinical Practice.
Study End Points
The primary end point of the original studies was
change in HbA1c level from baseline to week 24.
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level from baseline according to visit over time and the
change in fasting plasma glucose (FPG) from baseline
to week 24. Other end points included the change in
patient weight from baseline to week 24 and the use of
rescue medication. Rescue medication for hyperglyce-
mia (conﬁrmed glucose level, fasting 4240 mg/dL in
weeks 1–12,4200 mg/dL in weeks 13–24, or random
test result 4400 mg/dL; Z2 measurements on differ-
ent days, one performed after an overnight fast) was
permitted during randomized treatment. Doses of
background diabetes medications were kept stable
during screening, run-in, and the ﬁrst 12 weeks of
randomized treatment, after which adjustments were
permitted. Any adjustment of background therapies
and/or the induction of new antidiabetes therapy were
therefore regarded as rescue therapy during this phase.
Only introduction of new antidiabetes therapy was
regarded as rescue therapy in weeks 13 through 24.
The choice of rescue therapy was at the investigator’s
discretion but excluded other DPP-4 inhibitors and
GLP-1 agonists.
Safety was assessed according to incidence and
intensity of adverse events (AEs), drug-related AEs,
serious AEs, and discontinuation due to AEs. Hypo-
glycemic episodes were regarded as AEs and were
classiﬁed as previously reported.24 All cardiovascular
events were adjudicated by an independent expert
committee.Statistical Analyses
Efﬁcacy analyses were performed on individual
patient data by using the full analysis set, which
comprised all randomized patients with a reportedLinagliptin (n = 122)
Discontinued (n = 16)
Adverse event (5)
Lack of efficacy (0)
Protocol violation (6)
Lost to follow-up (2)
Refused to continue (0)
Other (3)
Completed (n = 106 [87%])
Figure 1. Patient disposition.
November 2014duration of T2DM of 410 years, who were treated
with Z1 dose of study drug, and who had a baseline
measurement and Z1 on-treatment HbA1c measure-
ment. The changes in mean HbA1c and FPG from
baseline to week 24 were compared between the
linagliptin and placebo groups in the pooled popula-
tion by using an ANCOVA model that included
treatment, continuous baseline HbA1c level, previous
use of insulin, study, and treatment-by-study interac-
tion; the model for FPG also included continuous
baseline FPG. Missing data were imputed by using a
last-observation-carried-forward approach. Safety
analyses were performed on the treated set, which
comprised all patients randomized to treatment who
received Z1 dose of study drug.RESULTS
Patient Disposition and Baseline Characteristics
In total, 202 patients with a reported T2DM
duration of 410 years received either linagliptin 5
mg once daily (n ¼ 122) or placebo (n ¼ 80)
(Figure 1). The full analysis set comprised 117 and
75 patients in the linagliptin and placebo groups,
respectively. Median exposure to linagliptin and
placebo was 169.0 days; maximal exposure was 177
and 180 days for linagliptin and placebo. Of the 202
patients in the treated set, 68 (33.7%) were from the
United States, 36 (17.8%) from Canada, 37 (18.3%)
from Australia, and 61 (30.2%) from Europe.
Baseline characteristics are shown in Tables I and
II. As expected for subjects with long-standing dia-
betes, the overall population comprised mainly older
patients with a mean (SD) age of 69.1 (10.0) years
(70.8 [9.6] years for linagliptin and 66.6 [10.2] yearsPlacebo (n = 80)
Discontinued (n = 16)
Adverse event (3)
Lack of efficacy (1)
Protocol violation (4)
Lost to follow-up (2)
Refused to continue (2)
Other (4)
Completed (n = 64 [80%])
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Table I. Baseline demographic and clinical characteristics of the treated set of patients.
Characteristic Linagliptin (n ¼ 122) Placebo (n ¼ 80)
Age, y
Mean (SD) 70.8 (9.6) 66.6 (10.2)
Median (minimum–maximum) 72.5 (42–91) 71.0 (37–89)
Age groups, no. (%)
o75 y 78 (63.9) 62 (77.5)
Z75 y 44 (36.1) 18 (22.5)
Sex, no. (%)
Male 78 (63.9) 44 (55.0)
Female 44 (36.1) 36 (45.0)
Race, no. (%)
White 87 (71.3) 42 (52.5)
Black 32 (26.2) 38 (47.5)
Asian 3 (2.5) 0
Body mass index, mean (SD), kg/m2 29.2 (4.6) 31.1 (5.2)
Body mass index (categorical), no. (%)
o25 kg/m2 20 (16.4) 8 (10.0)
25 to o30 kg/m2 58 (47.5) 28 (35.0)
Z30 kg/m2 44 (36.1) 44 (55.0)
Renal function stage (eGFR),* no. (%)
Stage 1 (Z90 mL/min/1.73 m2) 29 (24.2) 15 (20.0)
Stage 2 (60 to o90 mL/min/1.73 m2) 57 (47.5) 40 (53.3)
Stage 3 (30 to o60 mL/min/1.73 m2) 32 (26.7) 18 (24.0)
Stage 4 (o30 mL/min/1.73 m2) 2 (1.7) 2 (2.7)
*Estimated glomerular ﬁltration rate (eGFR [according to the Modiﬁcation of Diet in Renal Disease equation]) data were
missing for 2 patients in the linagliptin group and for 5 patients in the placebo group. Percentages were based on number of
patients without missing data (linagliptin, n ¼ 120, placebo, n ¼ 75).
Clinical Therapeuticsfor placebo). Mean body mass index was 30.0 (4.9)
kg/m2. Although many patients were receiving OAD
combination therapies and/or insulin at enrollment
(OAD combination therapy, 32%; insulin alone, 4%;
OAD and insulin combination therapy, 17%), the
mean baseline HbA1c level was 8.22% (1.08%), and
mean baseline FPG was 161.8 (49.2) mg/dL. These
values indicate that the overall control of hyperglyce-
mia was not in line with current recommended treat-
ment goals and may represent the progressive nature
of T2DM. Diabetes-related complications were also
common in this population, with approximately three
quarters of patients having diabetic kidney disease.
Moreover, cardiovascular conditions were very com-
mon with an overall high prevalence of macrovascular1598disease (83%). Based on these clinical characteristics,
polypharmacy had been initiated previously in many
patients, with 494% receiving at least 1 concomitant
therapy at the time of screening.
Efficacy
The adjusted mean (SE) change in HbA1c level from
baseline to week 24 was greater for linagliptin
(–0.62% [0.12%]) compared with placebo (0.04%
[0.12%]). The placebo-adjusted mean change in
HbA1c level from baseline to week 24 was 0.66%
(95% CI, 0.95 to 0.38; Po 0.0001). Mean adjusted
changes over time are shown in Figure 2. Patients with a
baseline HbA1c level Z7.5% who received linagliptin
were signiﬁcantly more likely to achieve an HbA1cVolume 36 Number 11
Table II. Baseline diabetes characteristics of the full analysis set of patients.
Characteristic Linagliptin (n ¼ 117) Placebo (n ¼ 75)
HbA1c, mean (SD), % 8.07 (0.89) 8.45 (1.31)
HbA1c category, no. (%)
o7.0% 7 (6.0) 2 (2.7)
7.0% to o8.0% 53 (45.3) 34 (45.3)
8.0% to o9.0% 40 (34.2) 19 (25.3)
Z9.0% 17 (14.5) 20 (26.7)
FPG, mean (SD), mg/dL 157.3 (39.4) 168.8 (61.2)
Antidiabetic drugs at enrollment, no. (%)
Insulin 5 (4.3) 2 (2.7)
Metformin 32 (27.4) 30 (40.0)
Metformin þ glinide 1 (0.9) 0
Metformin þ insulin 12 (10.3) 10 (13.3)
Metformin þ sulfonylurea 39 (33.3) 20 (26.7)
Metformin þ sulfonylurea þ α-glucosidase inhibitor 1 (0.9) 0
Metformin þ sulfonylurea þ insulin 7 (6.0) 0
Sulfonylurea 15 (12.8) 10 (13.3)
Sulfonylurea þ insulin 3 (2.6) 1 (1.3)
None 2 (1.7) 2 (2.7)
Relevant medical history,* no. (%)
Diabetic retinopathy 21 (17.2) 9 (11.3)
Diabetic nephropathy 10 (8.2) 5 (6.3)
Diabetic neuropathy 18 (14.8) 16 (20.0)
Diabetic foot 4 (3.3) 2 (2.5)
Coronary artery disease 21 (17.2) 14 (17.5)
Peripheral artery occlusive disease 6 (4.9) 5 (6.3)
Cerebrovascular disease 8 (6.6) 5 (6.3)
Hypertension 97 (79.5) 68 (85.0)
Microvascular disease† 36 (29.5) 25 (31.3)
Macrovascular disease‡ 99 (81.1) 68 (85.0)
HbA1c ¼ glycosylated hemoglobin; FPG ¼ fasting plasma glucose.
*Based on the treated set: linagliptin, n ¼ 122; placebo, n ¼ 80.
†Includes diabetic retinopathy, nephropathy, and neuropathy.
‡Includes coronary artery disease, peripheral artery occlusive disease, cerebrovascular disease, and hypertension.
R. Lajara et al.level o7.5% (odds ratio, 2.588 [95% CI, 1.148 to
5.833]; P ¼ 0.0218). The proportion of patients
achieving an HbA1c level o7.5% in each HbA1c
baseline category is shown in Figure 3. The adjusted
mean change from baseline to week 24 in FPG was
–10.4 (5.7) mg/dL and 5.1 (6.1) mg/dL in patients
receiving linagliptin and placebo, respectively. The
placebo-adjusted mean change in FPG from baselineNovember 2014to week 24 was 15.5 mg/dL (95% CI, 29.6 to
1.3; P ¼ 0.0323).
Safety
Overall, linagliptin was well tolerated, with drug-
related AEs reported in 21.3% and 16.3% of
the linagliptin and placebo safety sets, respectively
(Table III). The frequency of premature discontinuation1599
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Figure 2. Mean adjusted change in glycosylated hemoglobin (HbA1c) from baseline over time (full analysis
set, last observation carried forward).
80
60
Pe
rc
en
ta
ge
 o
f P
at
ie
nt
s
40
20
0
n = 32
62.5
36.8
47.5
21.1
10.011.8
7.5% to <8.0% 8.0% to <9.0%
Baseline HbA1c
≥9.0%
n = 19 n = 40 n = 19 n = 17 n = 20
Linagliptin
Placebo
Figure 3. Proportion of patients achieving target
glycosylated hemoglobin (HbA1c) target
o7.5% (full analysis set, noncompleters
considered failure). Percentages were
calculated by using the number of
patients achieving HbA1c levels o7.5%
within a baseline HbA1c subgroup as the
numerator and the total number of
patients within that baseline HbA1c sub-
group as the denominator.
Clinical Therapeuticsfrom trial medication was lower with linagliptin
than with placebo (13.1% vs 20.0%). Although
chronic hyperglycemia is challenging for patients
with long-standing diabetes, no patients discontinued
treatment with linagliptin due to persistent elevated
blood glucose levels. In addition, fewer patients in
the linagliptin group (5.1%) than in the placebo
group (21.3%) required rescue medication. The most
common reasons for discontinuation of study drug
were occurrence of an AE (4.1% with linagliptin
vs 3.8% with placebo) and patient noncompliance
(4.9% with linagliptin vs 5.0% with placebo)
(Figure 1). One patient who received linagliptin
experienced an adjudicated cardiovascular event
(nonfatal ischemic stroke, judged unrelated to study
drug).
The incidence of investigator-reported hypogly-
cemia was higher in patients receiving linagliptin
(25.4%) compared with placebo (12.5%). However,
no severe hypoglycemic events were reported with
linagliptin. Notably, in a subgroup of patients who
did not have any background sulfonylurea use (n ¼
105), the incidence of hypoglycemia was similar for
the linagliptin and placebo groups (12.5% and
12.2%, respectively) (Table IV).
At baseline, patients’ mean (SE) weight was 84.6
(1.6) kg for the linagliptin group and 89.5 (2.3) kg for
the placebo group. At week 24, no clinically relevant
differences in adjusted mean changes in weight were
observed for patients with available data (adjusted
mean change was –0.1 [0.4] kg with linagliptin
and –1.1 [0.5] kg with placebo).1600DISCUSSION
T2DM is a chronic condition characterized by progres-
sive loss of β-cell mass and function.8–10 The reduced
capacity of pancreatic β cells to release sufﬁcient
amounts of insulin aggravates hyperglycemia, and
glucose-lowering combination strategies (eventually
including exogenous insulin) are required to maintain
or restore adequate glycemic control. In addition toVolume 36 Number 11
Table III. Summary of adverse events (AEs) in the treated set of patients.
AE
Linagliptin
(n ¼ 122)
Placebo
(n ¼ 80)
Patients with Z1 AE, % 71.3 78.8
Patients with Z1 drug-related AE, % 21.3 16.3
Patients with AEs leading to discontinuation of trial medication, % 4.1 3.8
Patients with Z1 serious AE, %* 6.6 5.0
Fatal 0 0
Life-threatening 0 0
Requiring hospitalization 6.6 5.0
*None of the serious AEs was considered study drug related by the investigator.
R. Lajara et al.reduced β-cell function in long-standing T2DM, pancre-
atic α cells release an increased amount of postprandial
glucagon that in turn stimulates the liver to enhance
hepatic glucose production. This paracrine imbalance in
β- and α-cell cross-talk and homeostasis further under-
mines therapeutic glucose-lowering efforts. Primary and
secondary treatment failures have previously been re-
ported with traditional oral glucose-lowering therapies
in patients with newly diagnosed or longer-standingTable IV. Summary of investigator-reported hypoglyc
hypoglycemic event (treated set).
Event
Linag
(n ¼
Investigator-reported hypoglycemia* 25
In patients with hypoglycemia†
Any asymptomatic hypoglycemia 11 (
Any documented symptomatic
hypoglycemia
27 (
Pseudo-hypoglycemia 1 (
SU ¼ sulfonylurea.
*Percentage of patients treated.
†Percentage of patients with hypoglycemia. Asymptomatic hypog
of hypoglycemia but with a measured plasma glucose co
hypoglycemia is an event during which typical symptoms of
glucose concentration of r70 mg/dL. Pseudo-hypoglycemia is
symptoms of hypoglycemia with a measured plasma glucose c
higher than the number of patients with hypoglycemic events d
November 2014T2DM; however, those studies did not include incretin-
based therapies.10–15 Evidence that pancreatic effects of
oral DPP-4 inhibition could lead to an overall improve-
ment in glycemic control in patients with long-standing
T2DM is therefore still limited.
The present pooled analysis found that linagliptin,
an oral, once-daily DPP-4 inhibitor, was well tolerated
and signiﬁcantly improved hyperglycemia in patients
with T2DM for 410 years and, to our knowledge, isemic events according to characteristics of the
All Patients Patients With No SU
liptin
122)
Placebo
(n ¼ 80)
Linagliptin
(n ¼ 56)
Placebo
(n ¼ 49)
.4 12.5 12.5 12.2
35.5) 5 (50.0) 1 (14.3) 4 (66.7)
87.1) 6 (60.0) 6 (85.7) 3 (50.0)
3.2) 0 1 (14.3) 0
lycemia is an event not accompanied by typical symptoms
ncentration of r70 mg/dL. Documented symptomatic
hypoglycemia are accompanied by a measured plasma
an event during which the patient reports any of the typical
oncentration 470 mg/dL. Sum across categories may be
ue to multiple occurrences of hypoglycemia.
1601
Clinical Therapeuticsthe only available dataset of a DPP-4 inhibitor in this
challenging group. Many subjects included in this
analysis were elderly and had a signiﬁcant prevalence
of diabetes-related vascular complications and dia-
betic kidney disease. Guidelines commonly recom-
mend less stringent goals for older subjects with
long-standing disease and concomitant vascular dis-
ease.25–27 This recommendation is partly because
these patients are unlikely to beneﬁt from the long-
term consequences of more substantial reduction and
partly because the risk of hypoglycemia may be
increased to an unacceptable level. Rather than the
general HbA1c target of o7.0%, a target of o7.5%
may therefore be appropriate for these patients.
Notably, 62.5% of patients with a baseline HbA1c
level ofZ7.5% ando8% in this analysis, and 47.5%
with baseline values of Z8% and o9%, were able to
reach a goal ofo7.5% with linagliptin therapy. These
results were achieved with an overall low incidence of
hypoglycemic events (12.5%) when linagliptin was
given without concomitant sulfonylureas. The inci-
dence of hypoglycemia with linagliptin use in the
whole population was 25.4% (vs 12.5% with pla-
cebo); however, no severe episodes of hypoglycemia
were reported.
The efﬁcacy results observed in this pooled analysis
are consistent with the individual studies from the
linagliptin clinical trial development program that,
overall, comprised patients at earlier stages of
T2DM.28–30 Notably, the placebo-corrected mean
change in HbA1c of –0.66% (baseline, 8.22%) pre-
sented in this pooled analysis is very similar to the
reduction of –0.69% (baseline, 8.00%) that was
observed in a trial of linagliptin monotherapy in
patients not receiving any other glucose-lowering
treatment at randomization.30 This ﬁnding suggests
that linagliptin is efﬁcacious in those with a long
history of T2DM as well as in patients with relatively
short duration of disease.
Our results are also consistent with several studies
that included a high proportion of patients with a
reported disease duration of 45 years. In a 52-week
trial assessing the efﬁcacy and safety of linagliptin in
patients with T2DM and severe renal impairment,
96% of patients reported a duration of disease
45 years.31 In the study, the placebo-adjusted mean
change from baseline at week 52 in HbA1c was
–0.72% (95% CI, 1.03 to 0.41%; P o 0.0001).
An investigation of linagliptin added to basal insulin1602therapy also included a high proportion of elderly
patients and patients with diabetic kidney disease. The
placebo-adjusted mean change in HbA1c from baseline
at week 24 was –0.65% (95% CI, 0.74 to 0.55%;
P o 0.0001), and linagliptin was not associated with
an increased risk of hypoglycemia. Overall, 84% of
patients in this study reported a disease duration of
45 years; in this subgroup of patients, the placebo-
adjusted mean change in HbA1c from baseline at week
24 was –0.72%.32 Also of note, in a 24-week study of
the efﬁcacy and safety of linagliptin in patients with
T2DM inadequately controlled by metformin and a
sulfonylurea, 73% of patients reported a disease
duration of 45 years, and the placebo-adjusted mean
change in HbA1c from baseline at week 24 was
–0.62% (95% CI, 0.73 to 0.50%; P o 0.0001).33
In this study, the incidence of hypoglycemia was more
common with linagliptin than with placebo. This
ﬁnding is consistent with the present analysis and
with previous observations in which DPP-4 inhibitors
were used in combination with sulfonylureas.34 The
increased rate of hypoglycemia observed with DPP-4
inhibitors and sulfonylureas suggests residual β-cell
function even in patients with long-standing diabetes.
Apart from insulinotropic β-cell effects, other mecha-
nisms may contribute to the efﬁcacy of incretin agents in
long-standing T2DM. An early pilot study in 10 patients
with advanced T2DM and secondary failure of sulfony-
lurea therapy found that GLP-1 infusion effectively
lowered plasma glucose concentrations,35 suggesting
that there are β-cell–independent mechanisms involved.
Indeed, postprandial hyperglucagonemia is recognized
as contributing to the hyperglycemia of T2DM.36 In
addition, postprandial glucagon response is more
pronounced in elderly subjects compared with young
healthy subjects.37 The glucose-dependent inhibition of
glucagon secretion from pancreatic α cells by GLP-1 is
well characterized, and evidence suggests that the poten-
tiation of this action by DPP-4 inhibitors contributes to
the normalization of blood glucose levels.17–20 Results
from a study in patients with type 1 DM show that
DPP-4 inhibitor therapy lowers the prandial gluca-
gon response, suggesting an effect independent of
β-cell function.38 Therefore, we hypothesized that the
efﬁcacy of DPP-4 inhibition in patients with long-
standing diabetes is likely a result of the suppression of
glucagon secretion from pancreatic α cells in addition to
the residual remaining effects of glucose-dependent
stimulation of insulin release from the β cells in thisVolume 36 Number 11
R. Lajara et al.population. This is an exciting prospect for further
research, and glucagon levels should be measured in
future trials comprising patients with long-standing
T2DM. Although the bihormonal nature of glucose
control and the potential importance of glucagon in the
pathophysiology of diabetes were ﬁrst proposed in
1975,39 the perception of glucagon as only a minor
contributor to the diabetic phenotype has persisted.
However, a large body of evidence now supports the
concept of a bihormonal relationship between insulin
and glucagon, and an awareness of the role of glucagon
in diabetes and the value of glucagon suppression as a
therapeutic strategy has evolved.40
Although the results of this pooled analysis add to
the knowledge of the efﬁcacy and safety of linagliptin
in an important and previously understudied group,
the ﬁndings are limited by the retrospective nature of
the analysis. An inherent limitation of all pooled
analyses is that the patients were not randomized
speciﬁcally for the analysis in question, and therefore
it remains possible that baseline differences between
the groups could have confounded the results. The
analysis is also limited by the small sample size and
the relatively short-term nature of the original studies,
with a maximum duration of 6 months.
Ongoing studies are examining the effects of linaglip-
tin over the long term and will provide further insight
into its use in the context of long-standing T2DM. The
goal of the CARMELINA® (Cardiovascular and Renal
Microvascular Outcome Study with Linagliptin in Pa-
tients With Type 2 Diabetes Mellitus at High Vascular
Risk; NCT01897532) study is to investigate the effects
of linagliptin compared with placebo on major adverse
cardiovascular events (time to ﬁrst occurrence of car-
diovascular death, nonfatal myocardial infarction, non-
fatal stroke, or hospitalization for unstable angina) and
renal outcomes (time to ﬁrst occurrence of renal death,
sustained end-stage renal disease, or sustained decrease
of Z50% in estimated glomerular ﬁltration rate) over
an approximately 4-year period. Enrolled subjects will
be required to have a history of cardiovascular disease
and albuminuria, advanced diabetic kidney disease, or
both. Those individuals are expected to have a consid-
erably long duration of diabetes. In addition, the
CAROLINA® (Cardiovascular Outcome Study of Lina-
gliptin Versus Glimepiride in Patients With Type 2
Diabetes; NCT01243424) study has enrolled 6103
patients with T2DM at high cardiovascular risk or with
cardiovascular complications.41 Baseline results indicateNovember 2014that overall, 59% of patients have a reported T2DM
duration of 45 years. CAROLINA is the only long-
term cardiovascular outcomes trial of a DPP-4 inhibitor
to include an active sulfonylurea comparator, and it will
also include a long-term β-cell function substudy.
CONCLUSIONS
Compared with patients with shorter disease duration,
patients with long-standing T2DM are commonly older
and have decreased β-cell function and mass. More-
over, this vulnerable patient population is characterized
by concomitant macrovascular and microvascular co-
morbidities. However, clinical evidence for novel anti-
diabetes therapies such as DPP-4 inhibitors is scarce in
this population. The present pooled analysis found that
the efﬁcacy of linagliptin was maintained in patients
with long-standing T2DM, as evidenced by the extent
of glucose lowering comparable to that observed in
linagliptin trials which largely included patients in
earlier stages of disease. This ﬁnding is intriguing and
suggests that in addition to the β-cell–dependent effects
of linagliptin, other β-cell–independent mechanisms
also signiﬁcantly affect glucose control. We therefore
propose that the regulation of glucagon release from
pancreatic α cells by DPP-4 inhibitors may be of
particular relevance for control of hyperglycemia in
patients with long-standing T2DM.
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